ZX703 is a proteolysis targeting chimera (PROTAC), that is a degrader of GPX4 through the ubiquitin-proteasome and the autophagy-lysosome with a DC50 of 0.315 µM. It induces the accumulation of lipid reactive oxygen species (ROS), thereby inducing ferroptosis cancer cells.

ZX703 is a proteolysis targeting chimera (PROTAC), that is a degrader of GPX4 through the ubiquitin-proteasome and the autophagy-lysosome with a DC50 of 0.315 µM. It induces the accumulation of lipid reactive oxygen species (ROS), thereby inducing ferroptosis cancer cells.

ZX703 is a proteolysis targeting chimera (PROTAC), that is a degrader of GPX4 through the ubiquitin-proteasome and the autophagy-lysosome with a DC50 of 0.315 µM. It induces the accumulation of lipid reactive oxygen species (ROS), thereby inducing ferroptosis cancer cells.

HRS-4642 is a selective inhibitor of KRAS G12D with a Kd value of 0.083 nM. It exhibits robust anti-cancer activity against KRAS G12D-mutant cancers both in vitro and in vivo.

HRS-4642 is a selective inhibitor of KRAS G12D with a Kd value of 0.083 nM. It exhibits robust anti-cancer activity against KRAS G12D-mutant cancers both in vitro and in vivo.

HRS-4642 is a selective inhibitor of KRAS G12D with a Kd value of 0.083 nM. It exhibits robust anti-cancer activity against KRAS G12D-mutant cancers both in vitro and in vivo.

Ladarixin(DF 2156A free base) is a small molecule, orally available, allosteric and non-competitive antagonist of dual CXCR1 and CXCR2. It is able to reduce the acute and chronic neutrophilic influx, and can be used in research of Asthma, Idiopathic Pulmonary Fibrosis, Influenza-A infection and COPD, cutaneous and uveal melanoma conditions.

Ladarixin(DF 2156A free base) is a small molecule, orally available, allosteric and non-competitive antagonist of dual CXCR1 and CXCR2. It is able to reduce the acute and chronic neutrophilic influx, and can be used in research of Asthma, Idiopathic Pulmonary Fibrosis, Influenza-A infection and COPD, cutaneous and uveal melanoma conditions.

HRS-4642 is a selective inhibitor of KRAS G12D with a Kd value of 0.083 nM. It exhibits robust anti-cancer activity against KRAS G12D-mutant cancers both in vitro and in vivo.

NNC 55-0396 is a highly selective T-type calcium channel blocker with an IC50 value of 6.8 μM for Cav3.1 T-type channels. NNC 55-0396 can be used for the research of neurological disease research.